/
/
Halted Selinexor Clinical Trials Now Resume in Multiple Myeloma
Halted Selinexor Clinical Trials Now Resume in Multiple Myeloma image
Halted Selinexor Clinical Trials Now Resume in Multiple Myeloma
Posted Mar 31, 2017

On March 10, 2017, the FDA put a hold on all Selinexor clinical trials from Karyopharm. According to the FDA, the hold was placed on the drug due to incomplete documentation related to serious adverse events associated with selinexor. The hold was NOT placed due to any information regarding patient deaths or safety profile information. New patient recruiting was halted although patients already in selinexor trials were allowed to continue on trial.

Karyopharm has amended their investigator's brochure and as of March 30, 2017, the hold has now been lifted. Patients can now continue to join clinical trials involving selinexor. To date, more than 1,900 patients have been treated with selinexor in clinical trials across a variety of cancers.

Selinexor is a SINE (Selective Inhibitor of Nuclear Export) that binds to and stops the nuclear export protein XP01. Selinexor helps accumulate tumor suppressor proteins in the cell nucleus which then amplifies tumor suppression.

Selinexor made a splash at last year's American Society of Hematology conference due to the significant impact it had for highly relapsed and refractory myeloma patients.

It is currently being tested in a clinical trial called the STORM trial with low dose dexamethasone. It will be tested with typical myeloma "backbone" therapies in the STOMP trial. A new Phase III study is planned using selinexor with bortezomib and low-dose dexamethasone in the BOSTON trial.

To find all myeloma clinical trials using selinexor, click here:

All Selinexor Clinical Trials

To learn more about the STORM trial, click here:

STORM Myeloma Clinical Trial

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811